Exploration of pathomechanism using comprehensive analysis of serum cytokines in polymyositis/dermatomyositis-interstitial lung disease

被引:43
作者
Matsuda, Shogo [1 ]
Kotani, Takuya [1 ]
Ishida, Takaaki [1 ]
Fukui, Keisuke [2 ]
Fujiki, Youhei [1 ]
Suzuka, Takayasu [1 ]
Nagai, Koji [1 ]
Hata, Kenichiro [1 ]
Shoda, Takeshi [3 ]
Isoda, Kentaro [3 ]
Ito, Yuri [2 ]
Makino, Shigeki [1 ]
Takeuchi, Tohru [1 ]
Arawaka, Shigeki [1 ]
机构
[1] Osaka Med Coll, Dept Internal Med 4, Daigaku Machi 2-7, Takatsuki, Osaka 5698686, Japan
[2] Osaka Med Coll, Res & Dev Ctr, Dept Med Stat, Takatsuki, Osaka, Japan
[3] Yodogawa Christians Hosp, Dept Rheumatol, Osaka, Japan
关键词
polymyositis; dermatomyositis; interstitial lung disease; cytokines; CLINICALLY AMYOPATHIC DERMATOMYOSITIS; POLYMYOSITIS; MYOSITIS; PROGNOSIS; ANTIBODY; FERRITIN; PROGRESS; MDA5;
D O I
10.1093/rheumatology/kez301
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives To elucidate the serum cytokine profile and address the pathomechanism of interstitial lung disease (ILD) complicated with PM/DM. Methods Forty patients with PM/DM-ILD were enrolled, and principal components analysis and cluster analysis were performed to classify patients into subgroups. Additionally, we compared cytokine profiles between the survivors and dead patients and between anti-melanoma differentiation-associated gene 5 antibody- and anti-aminoacyl tRNA synthetase antibody-positive ILD patients. We also examined the association of various cytokines with disease activity indicators and prognosis of ILD. Results The principal components analysis data allowed classification of the cytokine profile into three groups: group 1, neutrophilic and M1-macrophage-driven cytokines; group 2, type 1 Th cell-driven and M2-macrophage-induced cytokines; and group 3, M2-macrophage-driven cytokines. Cluster analysis showed the presence of PM/DM-ILD patient groups with high or low levels of total cytokines. Ninety percent of patients who died of ILD were included in clusters with high cytokine levels. Serum cytokine levels of all groups were significantly higher in the anti-melanoma differentiation-associated gene 5 antibody-positive patients than in the anti-aminoacyl tRNA synthetase antibody-positive patients. Groups 1 and 2 significantly correlated with known factors for poor prognosis, such as serum ferritin levels and alveolar-arterial oxygen difference. Serum cytokine levels of patients in group 1 were significantly higher initially and at 2 and 4 weeks in those who died. Conclusion These findings suggested that the activation of monocytes, macrophages and type 1 Th cells, and neutrophils play roles in the pathomechanism of PM/DM-ILD, and group 1 cytokines could be useful biomarkers for predicting prognosis of PM/DM-ILD.
引用
收藏
页码:310 / 318
页数:9
相关论文
共 50 条
[31]   Intravenous Immunoglobulin Therapy for Refractory Interstitial Lung Disease Associated with Polymyositis/Dermatomyositis [J].
Suzuki, Yuzo ;
Hayakawa, Hiroshi ;
Miwa, Seiichi ;
Shirai, Masahiro ;
Fujii, Masato ;
Gemma, Hitoshi ;
Suda, Takafumi ;
Chida, Kingo .
LUNG, 2009, 187 (03) :201-206
[32]   Interstitial lung disease in amyopathic dermatomyositis, dermatomyositis and polymyositis [J].
Cottin, V ;
Thivolet-Béjui, F ;
Reynaud-Gaubert, M ;
Cadranel, J ;
Delaval, P ;
Ternamian, PJ ;
Cordier, JF .
EUROPEAN RESPIRATORY JOURNAL, 2003, 22 (02) :245-250
[33]   Pneumomediastinum in Interstitial Lung Disease Associated With Dermatomyositis and Polymyositis [J].
Le Goff, Benoit ;
Cherin, Patrick ;
Cantagrel, Alain ;
Gayraud, Martine ;
Hachulla, Eric ;
Laborde, Fyriel ;
Papo, Thomas ;
Sibilia, Jean ;
Zabraniecki, Laurent ;
Ravaud, Philippe ;
Puechal, Xavier .
ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2009, 61 (01) :108-118
[34]   HMGB1 May Be a Biomarker for Predicting the Outcome in Patients with Polymyositis/Dermatomyositis with Interstitial Lung Disease [J].
Shu, Xiaoming ;
Peng, Qinglin ;
Lu, Xin ;
Wang, Guochun .
PLOS ONE, 2016, 11 (08)
[35]   Pretreatment mortality risk prediction model in patients with polymyositis/dermatomyositis-associated interstitial lung disease [J].
Gui, Xianhua ;
Li, Wangzhong ;
Jiang, Hanyi ;
Wang, Rujia ;
Yu, Min ;
Zhao, Tingting ;
Ma, Miao ;
Ding, Jingjing ;
Jin, Ziyi ;
Qiu, Yuying ;
Qiu, Xiaohua ;
Zhang, Yingwei ;
Cao, Min ;
Huang, Mei ;
Cao, Mengshu ;
Dai, Jinghong ;
Cai, Hourong ;
Xin, Xiaoyan ;
Xiao, Yonglong .
RMD OPEN, 2024, 10 (02)
[36]   KL-6: a serological biomarker for interstitial lung disease in patients with polymyositis and dermatomyositis [J].
Fathi, M. ;
Helmers, S. Barbasso ;
Lundberg, I. E. .
JOURNAL OF INTERNAL MEDICINE, 2012, 271 (06) :589-597
[37]   KL-6 is a long-term disease-activity biomarker for interstitial lung disease associated with polymyositis/dermatomyositis, but is not a short-term disease-activity biomarker [J].
Hanaoka, Masanori ;
Katsumata, Yasuhiro ;
Kawasumi, Hidenaga ;
Kawaguchi, Yasushi ;
Yamanaka, Hisashi .
MODERN RHEUMATOLOGY, 2019, 29 (04) :625-632
[38]   IL-15 is a biomarker involved in the development of rapidly progressive interstitial lung disease complicated with polymyositis/dermatomyositis [J].
Shimizu, T. ;
Koga, T. ;
Furukawa, K. ;
Horai, Y. ;
Fujikawa, K. ;
Okada, A. ;
Okamoto, M. ;
Endo, Y. ;
Tsuji, S. ;
Takatani, A. ;
Umeda, M. ;
Fukui, S. ;
Sumiyoshi, R. ;
Kawashiri, S. -Y ;
Iwamoto, N. ;
Igawa, T. ;
Ichinose, K. ;
Tamai, M. ;
Sakamoto, N. ;
Nakamura, H. ;
Origuchi, T. ;
Mukae, H. ;
Kuwana, M. ;
Kawakami, A. .
JOURNAL OF INTERNAL MEDICINE, 2021, 289 (02) :206-220
[39]   Risk factors for the recurrence of interstitial lung disease in patients with polymyositis and dermatomyositis: a retrospective cohort study [J].
Nakazawa, Maho ;
Kaneko, Yuko ;
Takeuchi, Tsutomu .
CLINICAL RHEUMATOLOGY, 2018, 37 (03) :765-771
[40]   miR-1 is a novel biomarker for polymyositis/dermatomyositis-associated interstitial lung disease [J].
Sugiyama, Yumiko ;
Yoshimi, Ryusuke ;
Takeno, Mitsuhiro ;
Kunishita, Yosuke ;
Kishimoto, Daiga ;
Kamiyama, Reikou ;
Kirino, Yohei ;
Ohno, Shigeru ;
Nakajima, Hideaki .
MODERN RHEUMATOLOGY, 2020, 30 (05) :878-883